This page brings together the Agency's latest information on diabetes. It lists:
This is a summary of the European public assessment report (EPAR) for Insulatard. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion...
This is a summary of the European public assessment report (EPAR) for Actrapid. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in...
This is a summary of the European public assessment report (EPAR) for Actraphane. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion...
This is a summary of the European public assessment report (EPAR) for Trajenta. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in...
Edistride is a diabetes medicine used for adults whose condition is not controlled well enough. In type 2 diabetes, it is used with appropriate diet and exercise in patients who cannot take metformin...
EMA’s human medicines committee (CHMP) has recommended granting an extension of indication to Victoza (liraglutide) to include the treatment of children and adolescents aged 10 years or older with type 2 diabetes. This medicine is already approved...
EMA’s human medicines committee (CHMP) has recommended for the first time an adjunct treatment to insulin in the form of a tablet for certain patients with type 1 diabetes mellitus. Dapagliflozin is already authorised in the European Union as...
Diabetes patients reminded of importance of preventative foot care The European Medicines Agency (EMA) is informing about a potential increased risk of lower limb amputation (mostly affecting the toes) in patients taking the SGLT2 inhibitors...
Recommendations for patients with kidney impairment updated in product information The European Medicines Agency (EMA) has concluded that metformin-containing medicines can now be used in patients with moderately reduced kidney function (GFR [...
Healthcare professionals should be aware of possible atypical cases The European Medicines Agency (EMA) has confirmed recommendations 1 to minimise the risk of diabetic ketoacidosis in patients taking SGLT2 inhibitors (a class of type 2 diabetes...
Healthcare professionals should be aware of possible atypical cases EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has finalised a review of SGLT2 inhibitors (a class of type 2 diabetes medicines) and has made recommendations to minimise...